Hanall Biopharma Overview
- Year Founded
-
1973
- Status
-
Public
- Employees
-
323
- Stock Symbol
-
009420
- Investments
-
9
- Share Price
-
$38.23
- (As of Thursday Closing)
Hanall Biopharma General Information
Description
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.
Contact Information
Website
www.hanall.comCorporate Office
- 644, Bongeunsa-ro
- Gangnam-gu
- Seoul, 06170
- South Korea
Corporate Office
- 644, Bongeunsa-ro
- Gangnam-gu
- Seoul, 06170
- South Korea
Hanall Biopharma Stock Performance
As of 12-Nov-2026, Hanall Biopharma’s stock price is $38.23. Its current market cap is $1.94B with 50.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $38.23 | $36.97 | $25.46 - $48.43 | $1.94B | 50.9M | 268K | -$0.34 |
Hanall Biopharma Financials Summary
As of 30-Jun-2026, Hanall Biopharma has a trailing 12-month revenue of $112M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,061,937 | 1,537,020 | 1,312,948 | 1,685,285 |
| Revenue | 112,082 | 109,044 | 101,832 | 103,186 |
| EBITDA | (16,508) | (1,925) | 1,845 | 4,043 |
| Net Income | (17,160) | (3,906) | (1,323) | 2,684 |
| Total Assets | 155,873 | 156,405 | 144,525 | 186,041 |
| Total Debt | 29,160 | 22,164 | 983 | 1,001 |
Hanall Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hanall Biopharma Patents
Hanall Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11926669-B2 | Anti-fcrn antibody or antigen binding fragment thereof with improved stability | Active | 16-Jun-2022 | ||
| US-20230391876-A1 | Anti-fcrn antibody or antigen binding fragment thereof with improved stability | Active | 16-Jun-2022 | ||
| US-20250223362-A1 | Anti-fcrn antibody or antigen binding fragment thereof with improved stability | Pending | 16-Jun-2022 | ||
| AU-2023281650-A1 | Anti-fcrn antibody or antigen binding fragment thereof with improved stability | Pending | 30-May-2022 | ||
| EP-4531912-A1 | Anti-fcrn antibody or antigen binding fragment thereof with improved stability | Pending | 30-May-2022 | C07K16/283 |
Hanall Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hanall Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hanall Biopharma Investments & Acquisitions (9)
Hanall Biopharma’s most recent deal was a Later Stage VC with Turn Biotechnologies for . The deal was made on 10-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Turn Biotechnologies | 10-May-2024 | Later Stage VC | Drug Discovery | ||
| Vincere Biosciences | 16-Oct-2023 | Later Stage VC | Drug Discovery | ||
| Alloplex Biotherapeutics | 09-Feb-2023 | Later Stage VC | Drug Discovery | ||
| NurrOn Pharmaceuticals | 30-Jul-2021 | Early Stage VC | Drug Discovery | ||
| Immunovant | 19-Jul-2019 | Early Stage VC | Drug Discovery |
Hanall Biopharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.55 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Hanall Biopharma Exits (2)
Hanall Biopharma’s most recent exit was on 10-May-2024 from Turn Biotechnologies. The exit was categorized as with 18 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Turn Biotechnologies | 10-May-2024 | Completed |
|
||
| Immunovant | 19-Jul-2019 | Early Stage VC | Completed |
|
Hanall Biopharma FAQs
-
When was Hanall Biopharma founded?
Hanall Biopharma was founded in 1973.
-
Where is Hanall Biopharma headquartered?
Hanall Biopharma is headquartered in Seoul, South Korea.
-
What is the size of Hanall Biopharma?
Hanall Biopharma has 323 total employees.
-
What industry is Hanall Biopharma in?
Hanall Biopharma’s primary industry is Drug Delivery.
-
Is Hanall Biopharma a private or public company?
Hanall Biopharma is a Public company.
-
What is Hanall Biopharma’s stock symbol?
The ticker symbol for Hanall Biopharma is 009420.
-
What is the current stock price of Hanall Biopharma?
As of 12-Nov-2026 the stock price of Hanall Biopharma is $38.23.
-
What is the current market cap of Hanall Biopharma?
The current market capitalization of Hanall Biopharma is $1.94B.
-
What is Hanall Biopharma’s current revenue?
The trailing twelve month revenue for Hanall Biopharma is $112M.
-
What is Hanall Biopharma’s annual earnings per share (EPS)?
Hanall Biopharma’s EPS for 12 months was -$0.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
